Peter Evan Harwin serves as Executive at Dianthus Therapeutics, Inc. /DE/, where they oversee executive responsibilities. Since joining the company, Peter Evan Harwin has executed 14 insider transactions totaling $29.7M, demonstrating a bullish approach to their equity position. Their most recent transaction on Dec 4, 2025 involved purchasing 1,360,000 shares valued at $18.2M.
Peter Evan Harwin currently holds 2,747,866 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Peter Evan Harwin has been a net buyer of DNTH stock. They have purchased $29.7M and sold $0 worth of shares.
Peter Evan Harwin's most recent insider trade was on Dec 4, 2025, when they purchased 1,360,000 shares at $13.41 per share.
Get notified when new Form 4 filings are submitted
| $19.00 |
| Discretionary |
| Sep 16, 2024 | ZBIO | $0 | Conversion | 41,130 | $N/A | Discretionary |
| Sep 16, 2024 | ZBIO | $0 | Conversion | 252,890 | $N/A | Discretionary |
| Sep 16, 2024 | ZBIO | $0 | Conversion | 709,794 | $N/A | Discretionary |
| Sep 16, 2024 | ZBIO | $5.1M | Purchase | 300,000 | $17.00 | Discretionary |
| Sep 16, 2024 | ZBIO | $0 | Conversion | 301,077 | $N/A | Discretionary |
| Apr 25, 2024 | SYRE | $0 | Option Exercise | 3,639,680 | $N/A | Discretionary |
| Mar 28, 2024 | APGE | $0 | Other | 55,913 | $N/A | Discretionary |
| Mar 28, 2024 | APGE | $0 | Other | 55,913 | $N/A | Discretionary |
| Jan 29, 2024 | APGE | $0 | Other | 51,166 | $N/A | Planned |
| Jan 29, 2024 | APGE | $0 | Other | 892,529 | $N/A | Planned |
| Jan 29, 2024 | APGE | $0 | Other | 51,166 | $N/A | Planned |
| Sep 29, 2023 | DNTH | $336.3K | Purchase | 24,670 | $13.63 | Discretionary |